HRMY
Harmony Biosciences HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.60B
P/E Ratio
10.19
EPS
$2.71
Beta
0.89
52W High
$40.87
52W Low
$25.52
50-Day MA
$31.33
200-Day MA
$33.24
Dividend Yield
—
Profit Margin
18.30%
Forward P/E
8.42
PEG Ratio
—
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
| Revenue (TTM) | $868.45M |
| Gross Profit (TTM) | $670.11M |
| EBITDA | $233.80M |
| Operating Margin | 15.80% |
| Return on Equity | 20.70% |
| Return on Assets | 11.50% |
| Revenue/Share (TTM) | $15.11 |
| Book Value | $15.07 |
| Price-to-Book | 1.84 |
| Price-to-Sales (TTM) | 1.84 |
| EV/Revenue | 1.143 |
| EV/EBITDA | 3.89 |
| Quarterly Earnings Growth (YoY) | -55.00% |
| Quarterly Revenue Growth (YoY) | 21.10% |
| Shares Outstanding | $57.87M |
| Float | $50.90M |
| % Insiders | 12.08% |
| % Institutions | 91.11% |
Analyst Ratings
Consensus ($42.00 target)
2
Strong Buy7
Buy1
Hold1
Strong SellData last updated: 4/8/2026